A Study of the Tumor Microenvironment Affecting the Efficacy of Immunotherapy for Esophageal Cancer - Trial NCT06219031
Access comprehensive clinical trial information for NCT06219031 through Pure Global AI's free database. This phase not specified trial is sponsored by Renmin Hospital of Wuhan University and is currently Completed. The study focuses on Esophageal Cancer. Target enrollment is 22 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Renmin Hospital of Wuhan University
Timeline & Enrollment
N/A
Dec 01, 2023
Jan 01, 2024
Primary Outcome
Immunotherapy efficacy,CRใPRใSDใPD
Summary
This study is a retrospective study of clinical specimens. The study subjects were patients
 with esophageal cancer who received immunotherapy. Tumor tissue specimens surgically removed
 from patients before treatment will be collected primarily. In situ immunohistochemistry and
 multicolor immunofluorescence will be performed. We hypothesize that there are differences in
 lipid metabolism-related proteins in tumor tissues and immune cells in the preexisting tumor
 microenvironment in patients with esophageal cancer prior to immunotherapy, and that there is
 a link between such differences and the efficacy of immunotherapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06219031
Non-Device Trial